Parkinson's Disease - Market Insights, Epidemiology and Market Forecast 2017 - 2025

  • ID: 4401843
  • Drug Pipelines
  • Region: Global
  • 69 Pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 4
Covers the Therapeutics Market Revenue, Treatment Practice/Algorithm and Forecasted Market Size of Parkinson's Disease (PD) from 2017 to 2025 Segmented by Seven Major Markets

FEATURED COMPANIES

  • Acorda therapeutics
  • Boehringer Ingelheim
  • Novartis
  • Orion Corporation
  • MORE
Parkinson’s Disease - Market Insights, Epidemiology and Market Forecast - 2025 provides an overview of Parkinson's disease (PD), epidemiology and market trend of the Parkinson's disease (PD) for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Parkinson's disease (PD) from 2017 to 2025 segmented by seven major markets. In addition, the report also includes the forecasted epidemiology of Parkinson's disease (PD) till 2025. It also covers market drivers, market barriers and unmet medical need.

This report provides the diagnosed cases of Parkinson's disease (PD). Changes in diagnostic practice over time and increase in aging population will slowly increase the diagnosed cases of PD. According to research, the prevalent population of Parkinson's disease (PD) is expected to reach up to XXX cases by the end of 2025 at a CAGR of 4.69% from 2015-2025. High prevalent cases were observed in United States as compared to EU5 and Japan.

The market size is driven by several approved drugs that are being used for the treatment of Parkinson's disease such as Neupro (UCB Group of Companies), Xadago (Newron Pharmaceuticals S.p.A.) and Exelon (Novartis).

United States contributes the major share of Parkinson's disease (PD) market as compared to EU5 countries and Japan. The therapeutic market of PD in 7MM is expected to reach USD 4.91 Billion in 2025 at the CAGR of XX% from 2015-2025.

Key Coverage and Benefits:
  • The report will help in developing business strategies by understanding the trends shaping and driving the global Parkinson's disease (PD) market.
  • Organize sales and marketing efforts by identifying the best opportunities for Parkinson's disease in US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
  • To understand the future market competition in the Parkinson's disease market and Insightful review of the key market drivers and barriers.
  • To understand the regulatory scenario in major markets.
  • The report provides historical as well as forecasted epidemiology of Parkinson's disease in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
  • The report also covers the detailed historical and forecasted Parkinson's disease market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
Note: Please allow up to 24 hours for delivery after payment has been made.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acorda therapeutics
  • Boehringer Ingelheim
  • Novartis
  • Orion Corporation
  • MORE
1. Report Introduction

2. Parkinson Disease Market Overview at a Glance

3. Total Market Share Distribution of Parkinson Disease for 7 MM in 2016

4. Total Market Share Distribution of Parkinson Disease for 7 MM in 2025

5. Parkinson Disease

6. Overview
6.1. Symptoms
6.2. Pathophysiology
6.3. Staging
6.4. Diagnosis

7. Parkinson’s disease (PD) Geography wise Diagnosed Cases

8. 7MM Diagnosed PD Cases in 2016

9. 7MM Diagnosed PD Cases in 2025

10. Epidemiology and Patient Population

11. Key Points

12. Epidemiology Forecast Overview
12.1. United States
12.2. Diagnosed Cases of Parkinson Disease in United States
12.3. Europe
12.4. Germany
12.5. Diagnosed Cases of Parkinson Disease in Germany
12.6. France
12.7. Diagnosed Cases of Parkinson Disease in France
12.8. United Kingdom
12.9. Diagnosed Cases of Parkinson Disease in United Kingdom
12.10. Spain
12.11. Diagnosed Cases of Parkinson Disease in Spain
12.12. Italy
12.13. Diagnosed Cases of Parkinson Disease in Italy
12.14. Japan

13. Diagnosed Cases of Parkinson Disease in Japan

14. Treatment Algorithm

15. Unmet Needs

16. Marketed Drugs
16.1.1. Top Marketed Drugs for Parkinson disease
16.1.2. Azilect: Teva Pharmaceutical Industries
16.1.3. Drug Description
16.1.4. Mechanism of Action
16.1.5. Regulatory Milestones
16.1.6. Advantages & Disadvantages
16.1.7. Safety and Efficacy of Azilect
16.1.8. Product Profile
16.1.9. Exelon/Exelon Patch: Novartis
16.1.10. Drug Description
16.1.11. Mechanism of Action
16.1.12. Regulatory Milestones
16.1.13. Advantages & Disadvantages
16.1.14. Safety and Efficacy of Exelon
16.1.15. Product Profile
16.1.16. Stalevo: Orion Corporation
16.1.17. Drug Description
16.1.18. Mechanism of Action
16.1.19. Regulatory Milestones
16.1.20. Advantages & Disadvantages
16.1.21. Safety and Efficacy of Stalevo
16.1.22. Product Profile
16.1.23. Comtan/Comtess: Orion Corporation
16.1.24. Drug Description
16.1.25. Mechanism of Action
16.1.26. Regulatory Milestones
16.1.27. Advantages & Disadvantages
16.1.28. Safety and Efficacy of Comtan/Comtess
16.1.29. Product Profile

17. Emerging Therapies

18. Major Pipeline drugs
18.1. Tozadenant
18.2. Advantages & Disadvantages
18.3. Product Profile
18.4. Clinical Development
18.5. Clinical Pipeline Activity
18.6. Ongoing Trials Information
18.7. Clinical Trial by Phase
18.8. CVT-301
18.9. Product Profile
18.10. Clinical Development
18.11. Clinical Pipeline Activity
18.12. Ongoing Trials Information
18.13. Clinical Trial by Phase
18.14. Gene Therapy: Future possible treatment option for Parkinson’s Disease

19. Parkinson Disease: Country-Wise Market Analysis

20. Total Market Size of Parkinson Disease for 7 MM (2015-2025)

21. Overview on Total Parkinson Disease Market Geography wise (2016 & 2025)

22. Overview on Total Parkinson Disease Market (2016 & 2025)
22.1. United States Market Size
22.2. Europe Market Size
22.2.1. Germany Market Size
22.2.2. France Market Size
22.2.3. United Kingdom Market Size
22.2.4. Spain Market Size
22.2.5. Italy Market Size
22.3. Japan Market Size

23. Market Drivers

24. Market Restraints

25. Appendix

26. Report Methodology

27. Consulting Services

28. Disclaimer

29. About

List of Tables
Table 1: Diagnosed Cases of Parkinson Disease in United States (2015-2025)
Table 2: Diagnosed Cases of Parkinson Disease in Germany (2015-2025)
Table 3: Diagnosed Cases of Parkinson Disease in France (2015-2025)
Table 4: Diagnosed Cases of Parkinson Disease in United Kingdom (2015-2025)
Table 5: Diagnosed Cases of Parkinson Disease in Spain (2015-2025)
Table 6: Diagnosed Cases of Parkinson Disease in Italy (2015-2025)
Table 7: Diagnosed Cases of Parkinson Disease in Japan (2015-2025)
Table 8: Classes of Drugs used for management of Parkinson’s Disease
Table 9: List of Marketed Drugs for Parkinson Disease
Table 10: List of Pipeline Phase III Drugs for Parkinson Disease
Table 11: List of Pipeline Phase II Drugs for Parkinson Disease
Table 12: Tozadenant, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: CVT-301, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: Total 7 Major Market Size of Parkinson’s disease in USD Million (2015-2025)
Table 17: United States Market Size of Parkinson Disease in USD Million, (2015-2025)
Table 18: Germany Market Size of Parkinson Disease in USD Million, (2015-2025)
Table 19: France Market Size of Parkinson Disease in USD Million, (2015-2025)
Table 20: United Kingdom Market Size of Parkinson Disease in USD Million, (2015-2025)
Table 21: Spain Market Size of Parkinson Disease in USD Million, (2015-2025)
Table 22: Italy Market Size of Parkinson Disease in USD Million, (2015-2025)
Table 23: Japan Market Size of Parkinson Disease in USD Million, (2015-2025)

List of Figures
Figure 1: Types of Parkinson Disease
Figure 2: Pathophysiology of Parkinson’s Disease
Figure 3: Diagnosed Cases of Parkinson Disease in United States (2015-2025)
Figure 4: Diagnosed Cases of Parkinson Disease in Germany (2015-2025)
Figure 5: Diagnosed Cases of Parkinson Disease in France (2015-2025)
Figure 6: Diagnosed Cases of Parkinson Disease in United Kingdom (2015-2025)
Figure 7: Diagnosed Cases of Parkinson Disease in Spain (2015-2025)
Figure 8: Diagnosed Cases of Parkinson Disease in Italy (2015-2025)
Figure 9: Diagnosed Cases of Parkinson Disease in Japan (2015-2025)
Figure 10: Treatment Algorithm of Parkinson’s Disease
Figure 11: Treatment Algorithm of Parkinson’s Disease - continued
Figure 12: Tozadenant, Clinical Trials by Zone (%), 2017
Figure 13: Tozadenant, Clinical Trials by Trial status (%), 2017
Figure 14: CVT-301, Clinical Trials by Zone (%), 2017
Figure 15: CVT-301, Clinical Trials by Trial status (%), 2017
Figure 16: Total 7 Major Market Size of Parkinson’s disease in USD Millions (2015-2025)
Figure 17: Total Market Size of Parkinson Disease-Geography wise in USD Million, (2016)
Figure 18: Total Market Size of Parkinson Disease-Geography wise in USD Million, (2025)
Figure 19: Total Market Size of Parkinson Disease in USD Million, (2016)
Figure 20: Total Market Size of Parkinson Disease in USD Million, (2025)
Figure 21: United States Market Size of Parkinson Disease in USD Million, (2015-2025)
Figure 22: Germany Market Size of Parkinson Disease in USD Million, (2015-2025)
Figure 23: France Market Size of Parkinson Disease in USD Million, (2015-2025)
Figure 24: United Kingdom Market Size of Parkinson Disease in USD Million, (2015-2025)
Figure 25: Spain Market Size of Parkinson Disease in USD Million, (2015-2025)
Figure 26: Italy Market Size of Parkinson Disease in USD Million, (2015-2025)
Figure 27: Japan Market Size of Parkinson Disease in USD Million, (2015-2025)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Teva Pharmaceutical Industries Ltd.
  • Orion Corporation
  • Novartis
  • Boehringer Ingelheim
  • Newron Pharmaceuticals S.p.A.
  • Dainippon Sumitomo Pharma Co., Ltd.
  • Kyowa Hakko Kirin Co., Ltd.
  • ACADIA Pharmaceuticals Inc.
  • Acorda therapeutics
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll